Crescent Biopharma, Inc. · NASDAQ:CBIO
Crescent Biopharma — Glycomimetics — Merger or Acquisition (February 2025)
27 slides from Crescent Biopharma's merger presentation, Feb 28, 2025
Slide 1: Crescent Biopharma Overview
March 2025 Crescent Biopharma Overview
Slide 2: Disclaimers
2 Disclaimers This presentation is for informational purposes only and only a summary of certain information related to Crescent Biopharma, Inc . (“we”, “Crescent” or the “Company”) . It does not purport to be complete and does not contain all information that an investor may need to consider in mak
Slide 3: Crescent Biopharma aims to advance the next wave of innovation in cancer therapy
3 Crescent Biopharma aims to advance the next wave of innovation in cancer therapy 1. Anticipated expiration for filed provisional patent is 2045+ 2. Financing scheduled to close immediately prior to the closing of the merger with GlycoMimetics Notes: NSCLC: Non - small cell lung cancer. MoA : Mecha
Slide 4: Three oncology programs with best-in-class potential
4 Crescent is advancing three highly impactful oncology programs with best - in - class potential Notes: bsAb : Bispecific antibody. IND: Investigational New Drug application. PoC: Proof - of - concept CR - 001 PD - 1 x VEGF cooperative tetravalent bsAb Same MoA as ivonescimab Designed to reproduce
Slide 5: Multiple ways to win: pipeline enables optionality with combination therapies
5 Multiple ways to win: Crescent pipeline enables optionality with differentiating combination therapies Optimized Novel Monotherapies Synergistic Combination Approaches CR - 001 CR - 002 CR - 003 CR - 001 + CR - 002 CR - 001 + CR - 003 Engineered for: Best - in - class efficacy Efficacy across hist
Slide 6: Three key advances in oncology for next-generation combinations
6 Crescent leverages three key advances in oncology for next - generation combinations within unique portfolio EVOLUTION OF CHEMOTHERAPY Enhanced efficacy & safety via cooperativity Enhanced efficacy & safety via targeting ADC PD - (L)1 Cooperative bispecific PD - 1 x VEGF Systemic chemo CR - 002 CR
Slide 7: PD-(L)1-targeted therapies have transformed oncology
7 PD - (L)1 - targeted therapies, annualizing $50B+, have transformed oncology – with Keytruda now the best - selling drug in the world 1. 5 - year follow - up demonstrated mOS of 22.0 vs 10.6 months. 2. Notes: 1L: First - line. NSQ: Non - squamous. NSCLC: Non - small cell lung cancer. mOS : median
Slide 8: Ivonescimab doubled progression-free survival vs. Keytruda in a P3 NSCLC trial
8 Ivonescimab, a cooperative PD - 1 x VEGF bispecific, doubled progression - free survival vs. Keytruda in a P3 NSCLC trial Notes: HR: hazard ratio. PFS: progression - free survival. AE: adverse event. NSQ: Non - squamous SQ: Squamous. ORR: Objective response rat e. Akeso Biopharma has licensed ivon
Slide 9: Cooperative, tetravalent PD-1 x VEGF bispecific antibody
9 CR - 001 Cooperative, tetravalent PD - 1 x VEGF bispecific antibody
Slide 10: Ivonescimab's novel, cooperative MoA
10 Ivonescimab’s novel, cooperative MoA is hypothesized to drive enhanced anti - tumor activity while maintaining tolerability Sources: 2023 Zhong (SITC Poster); Summit Therapeutics VEGF drives tumor angiogenesis PD - L1 expression suppresses T cells Tumor Microenvironment (TME) VEGF PD - L1 PD - 1
Slide 11: Highly potent PD-1 x VEGF bsAb designed to recapitulate ivonescimab's pharmacology
11 CR - 001 is a highly potent PD - 1 x VEGF bsAb designed to recapitulate ivonescimab’s cooperative pharmacology Notes: IgG: Immunoglobulin G. scFvs : S ingle - chain variable fragment. ADCC: A ntibody - dependent cell - mediated cytotoxicity; PK: Pharmacokinetics. FcRn: N eonatal Fc receptor. CR -
Slide 12: Replicates ivonescimab's cooperative binding effect
12 CR - 001 replicates ivonescimab’s cooperative binding effect which leads to cooperative inhibition of PD - 1 signaling in presence of VEGF Notes: Ivonescimab generated internally based on published sequence. PD - 1 / PD - L1 signaling inhibition measured in RLU (relative light units), a measure o
Slide 13: Engineering replicates ivonescimab function with biophysical properties
13 CR - 001 engineering replicates ivonescimab function with biophysical properties that maximize flexibility in development Notes: CDR: Complementarity - determining region. CDC: Complement - dependent cytotoxicity. Fc: Fragment crystallizable. Ivonescimab’s unique structure and geometry – and resu
Slide 14: Potential to transform standard of care across oncology indications
14 CR - 001 has potential to transform SoC across a multitude of oncology indications, with numerous first - in - class opportunities Notes: EGFRm = mutant epidermal growth factor receptor. Sources: Keytruda Label; Opdivo Label; Tecentriq Label; Imfinzi Label; Libtayo Label; Bavencio Label; Jemperli
Slide 15: Late-stage competitor programs with P3 PFS and OS readouts
15 Development programs across key late - stage competitors include numerous P3s with PFS & OS readouts, paving the way for CR - 001 Notes: List of trials not exhaustive; BNT327 - 06 is a master protocol for two P2/3 sub - studies; BNT327 P2/3 in NSCLC announced Nov 2024 but details not yet availabl
Slide 16: Two parallel development paths
16 TWO PARALLEL DEVELOPMENT PATHS FOR CR - 001 Parallel clinical development paths offer potential for both first - in - class and lower risk opportunities for CR - 001 First - in - class opportunities Numerous indications with clinically meaningful anti - PD - (L)1 +/ - VEGF efficacy and potential
Slide 17: Phase 1 data offer potential for early acceleration
17 CR - 001 Phase 1 data offer potential for early acceleration – a rarity for a solid tumor oncology program High conviction in CR - 001’s clinical profile can be reached in ~9 - 12 months from Phase 1 initiation, offering potential for significant early value inflection Phase 1 interim proof - of
Slide 18: Only five known constructs with ivonescimab-like cooperative pharmacology
18 Only five known constructs with potential to exhibit ivonescimab - like cooperative pharmacology Sources: Internal data; Summit Therapeutics 2023 SITC Poster; Compass Therapeutics Jan 2025 Corporate Presentation and press release; Bio NTech 2024 ESMO Presentation; LaNova patent filings; Various p
Slide 19: Preclinical data reproduce ivonescimab's breakthrough pharmacology
19 CR - 001 preclinical data reproduce ivonescimab’s breakthrough pharmacology & are rapidly advancing to generate significant value Unprecedented third - party data validate PD - 1 x VEGF cooperativity Transformative MoA for $50B+ market CR - 001’s proprietary engineering is designed to replicate i
Slide 20: CR-002 & CR-003: Topoisomerase inhibitor ADCs against validated targets
20 CR - 002 & CR - 003 Topoisomerase inhibitor ADCs against validated targets
Slide 21: CR-002 and CR-003 are potentially best-in-class topoisomerase inhibitor ADCs
21 CR - 002 and CR - 003 are potentially best - in - class topoisomerase inhibitor ADCs, with applicability across solid tumors Potential to synergize with CR - 001 and other immunotherapies Each ADC can be leveraged in combination studies in solid tumors Validated, undisclosed solid tumor ADC targe
Slide 22: ADCs with topoisomerase inhibitor payloads show best-in-modality efficacy and safety
22 ADCs with topoisomerase inhibitor payloads have demonstrated best - in - modality efficacy and safety Notes: GEJ: Gastroesophageal junction. A: Approved. R: In registration. PN rates are weighted averages, by number of patients, acros s i ndications / trials and include PN, PSN, PMN, and PSMN whe
Slide 23: Corporate
23 Corporate
Slide 24: Executive Team and Board of Directors
24 Executive Team Jonathan Violin, PhD Interim CEO Chris Doughty Chief Business Officer Barbara Bispham General Counsel Ryan Lynch Chief Accounting Officer Jonathan Violin, PhD Alex Balcom Susan Moran, MD Peter Harwin Board of Directors Rapidly growing leadership team with deep experience building t
Slide 25: Financing expected to fund programs through key value-generating catalysts
25 Financing expected to fund Crescent programs through key anticipated value - generating catalysts Notes: mNSCLC : Metastatic non - small cell lung cancer. ES: Extensive stage. EGFRm: Mutant EGFR. Sources: ClinicalTrials.gov ; Company websites 2025 2026 Current cash expected to fund operations thr
Slide 26: Estimated capitalization following close of transactions
26 Estimated capitalization following close of transactions Pre - closing financing Shares of common stock outstanding Shares of common stock outstanding Shares of common stock Pre - funded warrants Series A shares 64,532,953 105,137,814 298,298,000 1,339,680,730 273,643,080 Estimated total shares o
Slide 27: Thank you
Thank you Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the Exchange Act and Section 27A of the Securities Act) concerning GlycoMimetics, Crescent, the proposed transactions and other matters. These forward-loo
Glycomimetics — Merger or Acquisition (February 2025) on 6ix